Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa
Sarah V. Leavitt
, Karen R. Jacobson, Elizabeth J. Ragan, Jacob Bor, Jennifer Hughes, Tara C. Bouton, Tania Dolby, Robin M. Warren, and Helen E. Jenkins
Author affiliations: Boston University, Boston, Massachusetts, USA (S.V. Leavitt, K.R. Jacobson, E.J. Ragan, J. Bor, T.C. Bouton, H.E. Jenkins); Boston Medical Center, Boston (K.R. Jacobson, E.J. Ragan, T.C. Bouton); University of the Witwatersrand, Johannesburg, South Africa (J. Bor); Stellenbosch University, Stellenbosch, South Africa (J. Hughes, R.M. Warren); Brown University, Providence, Rhode Island, USA (T.C. Bouton); Green Point Tuberculosis Laboratory, Cape Town, South Africa (T. Dolby); South African Medical Research Council Centre for Tuberculosis Research, Cape Town (R.M. Warren); Department of Science and Technology–National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Cape Town (R.M. Warren)
Figure 4. Healthcare facilities visited and movements between hospitals by patients in RR TB cohort, Western Cape Province, South Africa, 2012–2014. Inset maps show the Cape Town Metropole. A) All healthcare facilities visited <1 y after diagnosis. B) All movements made <1 y after diagnosis that involved TB hospitals. C) All movements made <1 y after diagnosis that did not involve a TB hospital. RR, rifampin-resistant; TB, tuberculosis.
Page created: January 29, 2021
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.